HOME >> BIOLOGY >> NEWS
Loblolly pine open for genetic engineering, research shows

COLLEGE STATION - The nation's most important commercial pine tree - the loblolly - has been successfully genetically engineered, researchers at the Texas Agricultural Experiment Station report in the journal Molecular Breeding.

The study, which proves a concept already demonstrated on many other plant species, will lead to further research that ultimately will enable scientists to improve the native southern pine with such traits as drought tolerance and disease- and pest-resistance, according to lead researcher Dr. Jean Gould, an Experiment Station molecular biologist.

"Loblolly pine has been challenging to genetically engineer because the genotype is very difficult to regenerate into plants in tissue culture," said Gould.

The transformation was done with a marker gene merely to prove that such genetic transfer could be done and that plants carrying the gene could be regenerated.

Gould's method for transforming plants - using a plant's meristem region for inoculation with Agrobacterium - was patented by the Experiment Station in 1992. The first plants transformed using this method were petunia and corn, followed by cotton and rice. She said using a plant meristem for transformation, rather than the traditional callus method, is a quicker and more universal way to transform plants because plant regeneration is simplified. In addition, the callus method does not work for many types of plants.

Loblolly pines dominate about 29 million acres in the southern United States, according to the U.S. Forest Service. The species grows rapidly as a young tree and lives about 75 years, but does not reach reproductive maturity for as many as 10 years after germination - meaning that traditional breeding programs would take decades to accomplish any improvements for the tree.

"While some crop plants have been selectively bred for more than 10,000 years, programs for the genetic improvement of pine are less than 100 years old
'"/>

Contact: Dr. Jean Gould
gould@tamu.edu
979-845-5078
Texas A&M University - Agricultural Communications
5-Sep-2002


Page: 1 2

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Rare childhood genetic syndrome identified
3. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
4. Scientists decipher genetic code of biothreat pathogen
5. Chemical genetics identifies SARS inhibitors
6. 22nd amino acid synthesized and added to genetic code of e. coli bacteria
7. The impact of genetic variations on the treatment of early rheumatoid arthritis
8. Adaptive changes in the genome may provide insight into the genetics of complex disease
9. New genetic hypothesis for the cause of autism
10. Fossils reveal direct link between global warming and genetic diversity in wildlife
11. A genetic disorder yields insight into genes and cognition

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Loblolly pine open for genetic engineering research shows

(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... announced today the acquisition of Turner Medical, Inc ., thus becoming a ... to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... A newly ... new ideas to lower the barriers to innovation in life sciences R&D. The Pistoia ... to two cash prizes of US$15,000 and a period of expert mentorship from a ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: